● Recruiting

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

Condition: Malignant Mesothelioma · Metastatic Malignant Solid Tumor · Advanced Solid Tumor · Sponsor: InSilico Medicine Hong Kong Limited

PhasePhase 1

Planned participants100

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).

This description comes directly from the study's public registry record.

Talk to the study team

Qinhan Chen · +86 021-50831718 · Insilico-Clinicaltrial@insilico.ai

Always discuss trial participation with your own doctor first.

Locations (10)

Sarah Cannon Research Institute at HealthONE	Denver, Colorado, United States	Recruiting
The University of Chicago Medical Center - Duchossois Center for Advanced Medicine	Chicago, Illinois, United States	Recruiting
University Hospitals Cleveland Medical Center	Cleveland, Ohio, United States	Recruiting
University of Pennsylvania - Abramson Cancer Center	Philadelphia, Pennsylvania, United States	Recruiting
SCRI Oncology Partners	Nashville, Tennessee, United States	Recruiting
NEXT Oncology - Austin	Austin, Texas, United States	Recruiting
Henan Cancer Hospital	Zhengzhou, Henan, China	Recruiting
Shanghai Pulmonary Hospital	Shanghai, Shanghai Municipality, China	Not Yet Recruiting
Cancer Hospital Chinese Academy of Medical Sciences	Beijing, China	Recruiting
Sun Yat-Sen University Cancer Center	Guangzhou, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06566079